Immatics N.V.

IMTX

$9.37

-0.95%

2026-09-04 12:37:35 EDT-$0.09

Healthcare

Biotechnology

NASDAQ

Active Trading

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily ...

Price Action of IMTX

$9.37

-0.95%-$0.09

High—

Low—

52W High-24.5%

Rel. vol—

Interval

Range3.1h

Volume—SMA5SMA10

—

Key Metrics of IMTX

Snapshot

Latest / TTM · 6 periods

Market Cap

$1.43B

ROCE

-52.9%

EV / EBITDA

-4.52x

-17.8% YoY

FCF Yield

-19.2%

-3.1% YoY

Cash Conversion Cycle

58.3d

Current Ratio

7.54

Quick take

Financial Highlights of IMTX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

100.0%

Net Margin

-495.3%

P/E Ratio

-5.13x

n/a

Debt / Equity

0.04

n/a

Current Ratio

7.54

Dividend Yield

0.0%

Understanding

Calendar of IMTX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.53 · Revenue $12.64M · 4 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.51 · Revenue $13.83M · 4 analysts

Financial Statements of IMTX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of IMTX

Acquisitions (A)

Since Jun 16, 2026

Disposals (D)

Since Jun 16, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Leadership Team of IMTX

11 executives

Name	Title	Compensation	Gender	Year Born	Status
Harpreet Singh	Chief Executive Officer, MD, Member of Management Board & Executive Director	EUR 1,006,940	—	1975	Active
Rainer Kramer	Chief Business Officer & Site Head Munich

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed TCR therapy in phase 3 SUPRAME for 2nd-line melanoma, with final PFS data expected in H1 2027. Positive phase 1b data [56% cORR, 6.1m PFS] and expansion into metastatic uveal melanoma support label expansion and broader PRAME pipeline ambitions.

Historical Employee Count of IMTX

Current

304

Change

+18.29%

Minimum

126

Maximum

304

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.54 vs -1.95	+21.1%	-0.43 vs -0.46	+6.0%
Revenue Surprise	$48.3M vs $46.9M	+2.9%	$7.6M vs $9.8M	-22.3%

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	304	20-F	Mar 5, 2026	View
Dec 31, 2024	257	20-F	Mar 27, 2025	View
Dec 31, 2023	190	20-F	Mar 21, 2024	View
Dec 31, 2022	148	20-F	Mar 22, 2023	View
Dec 31, 2021	126	20-F	Mar 23, 2022	View

Date	Executive	Title	Security	Side	Shares	Price
Aug 26, 2026	PERCEPTIVE ADVISORS LLC	director	Ordinary Shares	A	863,060	$8.69
Aug 14, 2026	Pepin James Nelson	officer: Gen Counsel and Corp Secretary	Stock Option (Right to Buy)	A	181,200	$9.44
Aug 14, 2026	Pepin James Nelson	officer: Gen Counsel and Corp Secretary	Restricted Stock Units	A	43,800	—
Jul 20, 2026	Pepin James Nelson	officer	—	—	0	—
Jun 16, 2026	Stone Adam Leo	director	Stock Option (Right to Buy)	A	48,000	$9.09

Immatics N.V.

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Related stocksBiotechnology

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Immatics Announces $150 Million Underwritten Offering

Immatics Announces Second Quarter 2026 Financial Results and Business Update

Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $20.80

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

FY2024 · Annual results

Recent Filings